Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%Martin Reck, Julie R. Brahmer, Tibor Csőszi et al.|Journal of Clinical Oncology|2021Cited by 1.1k
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%Julie R. Brahmer, Martin Reck, Delvys Rodríguez‐Abreu et al.|Annals of Oncology|2020Cited by 96